Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

Psychedelic News

Choose Ketamine Complete Seed Capital Raise to Expand Technology Platform Psychedeic-Chronicle-Logo-White
Psychedelic News

Choose Ketamine Complete Capital Raise to Expand Technology Platform

February 16, 2023

In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, has announced the completion of its seed financing round. Led by Manifestations Capital in collaboration with Notley Ventures and numerous industry veterans and thought leaders, this

Read More
Biomind Labs Secure Pre-IND Meeting, Seek FDA Feedback on New Triptax Depression Treatment Psychedeic-Chronicle-Logo-White
Psychedelic News

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

October 14, 2022

The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational New Drug (Pre-IND) meeting by the U.S. Food and Drug Administration (FDA) for new chemical entity Triptax™. Biomind Labs is devoted to crafting innovative pharmaceuticals for patients with neurological and psychiatric disorders, using

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment Psychedeic-Chronicle-Logo-White
October 10, 2022

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use Psychedeic-Chronicle-Logo-White
October 7, 2022

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently

Choose Ketamine Complete Seed Capital Raise to Expand Technology Platform Psychedeic-Chronicle-Logo-White
Psychedelic News

Choose Ketamine Complete Capital Raise to Expand Technology Platform

In a major milestone for mental health care, Austin-based Choose Your Horizon Inc., also known as Choose Ketamine, has announced the completion

February 16, 2023
Biomind Labs Secure Pre-IND Meeting, Seek FDA Feedback on New Triptax Depression Treatment Psychedeic-Chronicle-Logo-White
Psychedelic News

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that it has been granted a Pre-Investigational

October 14, 2022
Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment Psychedeic-Chronicle-Logo-White
Psychedelic News

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel

October 10, 2022
Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use Psychedeic-Chronicle-Logo-White
Psychedelic News

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for

October 7, 2022
atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial Psychedeic-Chronicle-Logo-White
Psychedelic News

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai has administered the first dosage of their VLS-01 synthetic DMT drug in their Phase 1 single-ascending dose (SAD) trial, with topline

October 7, 2022
Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio Psychedeic-Chronicle-Logo-White
Psychedelic News

Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio

Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual

September 30, 2022
Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression Psychedeic-Chronicle-Logo-White
Psychedelic News

Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression

Leading psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) has announced the completion of dose administration to 30

September 22, 2022
Revitalist Partners with Wake Network To Offer Psychedelics for Veterans Upon 300 Month over Month Growth Psychedeic-Chronicle-Logo-White
Psychedelic News

Revitalist Partners with Wake Network To Offer Psychedelics for Veterans Upon 300% Month over Month Growth

Revitalist Lifestyle and Wellness LTD. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) recently announced a new joint venture partnership with Wake Network, Inc.

September 14, 2022
Bright Minds Biosciences Announce Dosing of First Patient in Phase 1 Clinical Trial of BMB-101 for Dravet Syndrome Psychedeic-Chronicle-Logo-White
Psychedelic News

Bright Minds Biosciences Announce Dosing of First Patient in Phase 1 Clinical Trial of BMB-101 for Dravet Syndrome

Psychedelic biotechnology company Bright Minds Biosciences recently announced that it has dosed the first patient in a Phase I trial (NCT 05397041)

September 2, 2022
Mindset-Pharma-Expands-IP-Portfolio-Identifying-3-New-Families-of-Next-Generation-Psychedelic-Compounds Psychedeic-Chronicle-Logo-White
Psychedelic News

Mindset Pharma Expands IP Portfolio Identifying 3 New Families of Next-Generation Psychedelic Compounds

Drug discovery and development company Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced today the company has identified three additional families

August 31, 2022

Recent Posts

  • Choose Ketamine Complete Capital Raise to Expand Technology Platform
  • Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax
  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

Recent Comments

No comments to show.

Popular

Choose Ketamine Complete Seed Capital Raise to Expand Technology Platform

Choose Ketamine Complete Capital Raise to Expand Technology Platform

In a major milestone for mental health care, Austin-based Choose

Biomind Labs Secure Pre-IND Meeting, Seek FDA Feedback on New Triptax Depression Treatment

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

The well-known psychedelic biotech company Biomind Labs Inc. (NEO: BMND)

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS